DOP2003000621A - Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa - Google Patents

Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa

Info

Publication number
DOP2003000621A
DOP2003000621A DO2003000621A DO2003000621A DOP2003000621A DO P2003000621 A DOP2003000621 A DO P2003000621A DO 2003000621 A DO2003000621 A DO 2003000621A DO 2003000621 A DO2003000621 A DO 2003000621A DO P2003000621 A DOP2003000621 A DO P2003000621A
Authority
DO
Dominican Republic
Prior art keywords
inhibitors
triariloxiariloxipirimidin
metaloproteinase
trion
traloyloxyaryloxypyrimidine
Prior art date
Application number
DO2003000621A
Other languages
English (en)
Inventor
Lawrence Alan Reiter
Kevin Daniel Freemancook
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2003000621A publication Critical patent/DOP2003000621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se refiere a inhibidores trairiloxiariloxipirimidin-2,4,6-triona de metaloproteinasa de formula. En la que x,a,y,b,g,w, y R1 son como se define en la memoria descritiva, y a composiciones farmacéuticas y procedimientos de tratamiento de la inflamación, el cancer y otros trastornos.
DO2003000621A 2002-04-26 2003-04-01 Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa DOP2003000621A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37599002P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
DOP2003000621A true DOP2003000621A (es) 2003-10-31

Family

ID=29270744

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2003000621A DOP2003000621A (es) 2002-04-26 2003-04-01 Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa

Country Status (18)

Country Link
US (1) US7119201B2 (es)
EP (1) EP1501515B1 (es)
JP (1) JP2005529132A (es)
AR (1) AR039658A1 (es)
AT (1) ATE308325T1 (es)
AU (1) AU2003216677A1 (es)
BR (1) BR0309386A (es)
CA (1) CA2484067A1 (es)
DE (1) DE60302149T2 (es)
DO (1) DOP2003000621A (es)
ES (1) ES2250880T3 (es)
GT (1) GT200300082A (es)
MX (1) MXPA04009392A (es)
NI (1) NI200300045A (es)
PA (1) PA8571501A1 (es)
TW (1) TW200403998A (es)
UY (1) UY27772A1 (es)
WO (1) WO2003090752A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527598A (ja) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
DE60302150D1 (en) * 2002-04-26 2005-12-08 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
JP2005529889A (ja) * 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US8710038B2 (en) * 2004-09-17 2014-04-29 Exelixis, Inc. Pyrazole kinase modulators and methods of use
US9045442B2 (en) 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
GB201115937D0 (en) 2011-09-14 2011-10-26 Univ Aberdeen 18F-labelled compounds for use as positron emission imaging agents
EP3104861A4 (en) * 2014-02-14 2017-10-04 Warrell, Raymond P., Jr. Bifunctional compounds and use for reducing uric acid levels
WO2015127378A1 (en) 2014-02-21 2015-08-27 Medicomp Systems, Inc. Intelligent prompting of protocols
KR20170113529A (ko) 2014-09-25 2017-10-12 유니버시티 오브 노트르 담 듀락 비-베타 락탐 항생제
JP2018502896A (ja) 2015-01-22 2018-02-01 ピー．，ジュニア ワーレル，レイモンド 二機能性化合物および尿酸レベルを低下させるための使用
TWI771303B (zh) 2016-06-30 2022-07-21 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(一)
CN109476642B (zh) 2016-07-06 2022-01-25 阿奎斯特有限责任公司 化合物及其用于降低尿酸水平的用途
WO2018049404A1 (en) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Compounds for the treatment of clostridium difficile infection
LT3700902T (lt) 2017-10-27 2023-06-26 Boehringer Ingelheim International Gmbh Trpc6 inhibitoriai

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
DE19548624A1 (de) * 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69831233T2 (de) * 1997-06-21 2006-06-01 Roche Diagnostics Gmbh Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PA8498701A1 (es) * 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
EA200300409A1 (ru) * 2000-10-26 2003-08-28 Пфайзер Продактс Инк. Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
JP2005527598A (ja) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
DE60302150D1 (en) 2002-04-26 2005-12-08 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren

Also Published As

Publication number Publication date
CA2484067A1 (en) 2003-11-06
DE60302149D1 (de) 2005-12-08
JP2005529132A (ja) 2005-09-29
TW200403998A (en) 2004-03-16
PA8571501A1 (es) 2003-12-10
WO2003090752A1 (en) 2003-11-06
DE60302149T2 (de) 2006-07-20
US20040006057A1 (en) 2004-01-08
AR039658A1 (es) 2005-03-02
AU2003216677A1 (en) 2003-11-10
UY27772A1 (es) 2003-11-28
EP1501515B1 (en) 2005-11-02
ATE308325T1 (de) 2005-11-15
BR0309386A (pt) 2005-02-22
ES2250880T3 (es) 2006-04-16
EP1501515A1 (en) 2005-02-02
NI200300045A (es) 2005-07-08
US7119201B2 (en) 2006-10-10
MXPA04009392A (es) 2005-01-25
GT200300082A (es) 2004-04-19

Similar Documents

Publication Publication Date Title
PA8572101A1 (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
UY27777A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
UY26981A1 (es) Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona
ECSP003610A (es) Pirimidina-2,4,6 trionas inhibidores de metaloproteinas
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
UY28247A1 (es) Compuestos de benzopirano para uso en el tratamiento y la prevención de afecciones relacionadas con la inflamación.
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
TNSN07283A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
UY28145A1 (es) Nuevos compuestos farmaceuticos
UY26179A1 (es) Amidas sustituidas del ácido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporación de adenosina.
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b